ARTICLE SUMMARY:
Medtech and diagnostics dealmaking is flourishing amid a multi-year life sciences financing boom, as a sustained, robust IPO aftermarket motivates both traditional and non-traditional investors. Despite the enthusiasm, valuations remain comparatively reasonable. One blot on the good times: M&A volume is down.
Editor’s note: read our updated analysis about COVID-19’s financial impact on the device and diagnostics industries at our Community Blog.
2019’s robust life sciences financing climate has left a warm glow throughout the ecosystem, including in the diagnostics and devices sectors. The most salient feature of the current boom for these two sometimes sidelined fields is the sustained positive performance of IPOs and their aftermarket, a trend that looks poised to continue for most of 2020, barring unforeseen setbacks in the macroeconomy.
